Table 1.
COVID-19 in patients with hematologic malignancies (HM).
| Reference | Patient Population | Risk Factors | Clinical Severity | Mortality |
|---|---|---|---|---|
| [8] | 128 pts with HM (13 with COVID-19) Median age 35 y |
Co-bacterial infections | 10 pts required oxygen | 62% |
| [9] | 35 pts with HM and COVID-19 Median age 69 y |
Age, number of comorbidities | 40% | |
| [11] | 928 pts with cancer and COVID-19 Median age 66 y |
Age, male sex, smoking, number of comorbidities, ECOG > 2, active cancer | 14% admitted to ICU 12% required ventilation |
13% |
| [12] | 4966 pts with cancer and COVID-19 (10% with HM) Median age 66 y |
Age, male sex, obesity, CV and lung comorbidities, renal disease, diabetes mellitus, non-Hispanic black race, Hispanic ethnicity, worse ECOG, recent cytotoxic chemotherapy, HM | Hospitalization 58.7% | 14% |
| [13] | 1250 pts with HM (16 pts with COVID-19) | Age, number of comorbidities | Hospitalization 80% 12% admitted to ICU |
30% |
| [14] | 80 pts with HM and COVID-19 Mean age 69 y |
Age, intensive therapy | 39% | |
| [15] | 536 pts with HM and COVID-19 Median age 68 y |
Age, AML diagnosis, indolent and aggressive NHL, PC neoplasms, severe COVID-19 | 15% admitted to ICU | 36.9% |
| [16] | 219 pts with MPN (29 pts with COVID-19) Median age 62 y |
Presence of AAbs against type I IFN | Hospitalization 27.6% |
Pts: patients, ECOG: Eastern Cooperative Oncology Group; ICU: intensive care unit; CV cardiovascular; AML: acute myeloid leukemia; NHL non-Hodgkin lymphoma; PC plasma cell; MPN: myeloproliferative neoplasms; AAbs autoantibodies.